Information de reference pour ce titreAccession Number: | 00004628-201106000-00005.
|
Author: | Zhang, Rong-Xin 1,2; Wu, Xiao-Jun 1,2; Lu, Shi-Xun 1,2; Pan, Zhi-Zhong 1,2; Wan, De-Sen 1,2; Chen, Gong 1,2
|
Institution: | (1)Department of Colorectal Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, People's Republic of China. (2)State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, People's Republic of China.
|
Title: | The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.[Article]
|
Source: | Journal of Cancer Research & Clinical Oncology. 137(6):953-957, June 2011.
|
Abstract: | Purpose: Hand-foot syndrome (HFS) is a common adverse event that can be induced by capecitabine. It is hypothesized that capecitabine (Hoffmann-La Roche Inc.) based chemotherapy can cause overexpression of COX-2 in tumor and healthy tissue, which finally induced HFS in hands and feet. Based on this, we believed that a selected COX-2 inhibitor (celecoxib, Pfizer Pharmaceuticals LLC) could ease HFS. We designed a prospective clinical study to test the hypothesis.
Methods: From August 2008 to January 2010, 110 patients with stage II/III colorectal cancer who were eligible for adjuvant chemotherapy were enrolled in the study and divided into 4 groups by random, but 9 patients did not finish at least 4 cycles of chemotherapy. There were sixteen patients in capecitabine group, and fifteen patients in capecitabine and celecoxib group. Thirty-four patients were in XELOX (capecitabine plus oxaliplatine) group, and thirty-six patients in XELOX+ celecoxib group. All 101 patients finished chemotherapy and follow-up interviews.
Results: The group that had received capecitabine and celecoxib had a significantly reduced frequency of >grade 1 hand-foot syndrome (29 vs. 72% P < 0.001), and >grade 2 (11.76% vs. 30% P = 0.024). Five patients experienced grade 3 HFS in capecitabine group and only 1 patient had grade 3 HFS in capecitabine and celecoxib group. There were 5 patients in capecitabine group who refused to go on chemotherapy because of HFS, but there was none in capecitabine and celecoxib group.
Conclusions: From the result of this study, we could learn that celecoxib could reduce HFS that was induced by capecitabine. So we recommend that celecoxib can be used in capecitabine-based chemotherapy.
(C) 2011 Springer. Part of Springer Science Business Media
|
Author Keywords: | Hand-foot syndrome; Capecitabine; Celecoxib; Colorectal cancer; Adjuvant chemotherapy; Adverse event.
|
Language: | English.
|
Document Type: | Original Paper: PDF Only.
|
ISSN: | 0171-5216
|
NLM Journal Code: | hl5, 7902060
|
DOI Number: | https://dx.doi.org/10.1007/s0043...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |